HB-EGF Antibody (406316)

Recombinant Human HB‑EGF (Catalog # 259-HE) stimulates proliferation in the Balb/3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human HB‑EGF (5 ng/mL) is neutralized (green line) by increasing concentrations of Human HB-EGF Monoclonal Antibody (Catalog # MAB2591). The ND50 is typically 0.5-2.5 µg/mL.

Signaling pathways activated by PDGF-AA, PDGF-BB, HB-EGF, TCM, or VECM.(A) Decidualized St-T1b were starved in Opti-MEM and then treated for 5 or 30 min with PDGF-BB, HB-EGF, TCM or PDGF-AA. Levels of phosphorylated (p-) or total ERK1/2, Akt, and p38 were determined by Western blotting. (B) Decidualized hESC were starved in Opti-MEM and then treated for 5 min with PDGF-BB, HB-EGF, TCM, 5 individual VECM preparations, villous explant control medium (VECM-Co), or PDGF-AA. Western blotting was performed as above. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/23349855), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression and regulation of HER1 in St-T1b cells and hESCs.(A) Effect of decidualization on HER1 expression. Whole cell extracts from two individual hESC preparations or from St-T1b cells, non-decidualized (−) or decidualized (+), were immunoblotted for HER1 (antibody from New England Biolabs), and for GAPDH as a loading control. In addition, the levels of Nur77, alpha -SMA, MLC2 and phospho-MLC2 were analyzed. (B, C, D) Time-dependent downregulation of HER1 in response to HB-EGF or TCM. Non-decidualized (ND) or decidualized (D) St-T1b cells, maintained in Opti-MEM, were incubated with PDGF-BB, HB-EGF or TCM (20 or 100%) for 5 min (B) or 5, 30 and 60 min (C) and subjected to Western Blot analysis for HER1 (antibody from Santa Cruz). Decidualized St-T1b cells were stimulated with HB-EGF or TCM (100%) for 5, 30 and 60 min or 24 h (D) and analyzed for HER1 by Western blotting (antibody from Santa Cruz), followed by immunoblotting for phospho-ERK1/2 and phosphorylated (Ser473) and total Akt. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/23349855), licensed under a CC-BY license. Not internally tested by R&D Systems.

Signaling pathways activated by PDGF-AA, PDGF-BB, HB-EGF, TCM, or VECM.(A) Decidualized St-T1b were starved in Opti-MEM and then treated for 5 or 30 min with PDGF-BB, HB-EGF, TCM or PDGF-AA. Levels of phosphorylated (p-) or total ERK1/2, Akt, and p38 were determined by Western blotting. (B) Decidualized hESC were starved in Opti-MEM and then treated for 5 min with PDGF-BB, HB-EGF, TCM, 5 individual VECM preparations, villous explant control medium (VECM-Co), or PDGF-AA. Western blotting was performed as above. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/23349855), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression and regulation of HER1 in St-T1b cells and hESCs.(A) Effect of decidualization on HER1 expression. Whole cell extracts from two individual hESC preparations or from St-T1b cells, non-decidualized (−) or decidualized (+), were immunoblotted for HER1 (antibody from New England Biolabs), and for GAPDH as a loading control. In addition, the levels of Nur77, alpha -SMA, MLC2 and phospho-MLC2 were analyzed. (B, C, D) Time-dependent downregulation of HER1 in response to HB-EGF or TCM. Non-decidualized (ND) or decidualized (D) St-T1b cells, maintained in Opti-MEM, were incubated with PDGF-BB, HB-EGF or TCM (20 or 100%) for 5 min (B) or 5, 30 and 60 min (C) and subjected to Western Blot analysis for HER1 (antibody from Santa Cruz). Decidualized St-T1b cells were stimulated with HB-EGF or TCM (100%) for 5, 30 and 60 min or 24 h (D) and analyzed for HER1 by Western blotting (antibody from Santa Cruz), followed by immunoblotting for phospho-ERK1/2 and phosphorylated (Ser473) and total Akt. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/23349855), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, B/N
• Clone: 406316
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

HB-EGF Antibody (406316) Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human HB-EGF
  Asp63-Leu148
  Accession # Q53H93
• Specificity: Detects human HB-EGF in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross-react with recombinant human (rh) Amphiregulin, rhBTC, rhHRG-alpha , rhHRG-beta , rhEGF, rhTGF-alpha , recombinant mouse (rm) Epigen, or rmEpiregulin.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: HBEGF
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.5-2.5 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for HB-EGF Antibody (406316)

• diphtheria toxin receptor (heparin-binding epidermal growth factor-like growthfactor)
• Dtr
• DTRHEGFLdiphtheria toxin receptor (heparin-binding EGF-like growth factor)
• Dts
• DTSF
• HBEGF
• HB-EGF
• Hegfl
• heparin-binding EGF-like growth factor
• heparin-binding epidermal growth factor
• proheparin-binding EGF-like growth factor

Background

HB-EGF was originally purified based on its heparin-binding property and mitogenic activity on BALB-3T3 fibroblasts from the conditioned medium of the human U-937 histiocytic lymphoma cell line. The natural protein has an apparent molecular mass of 19-23 kDa and exists in multiple forms as a result of heterogenous O‑glycosylation and/or N-terminal truncation. In addition to fibroblasts, HB-EGF is also a potent mitogen for keratinocytes and smooth muscle cells but not for capillary endothelial cells. HB-EGF is produced in monocytes and macrophages. In addition, transcription of HB-EGF can be induced in vascular endothelial cells as well as aortic smooth muscle cells (SMC), suggesting that HB-EGF may have an important role in the pathogenesis of atherosclerosis.

HB-EGF is a member of the EGF family of mitogens which also include transforming growth factor-alpha (TGF-alpha ), amphiregulin (AR), rat schwanoma-derived growth factor (SDGF), vaccinia growth factor (VGF), and the various ligands for the Her2/ErbB2/Neu receptor. All these cytokines are derived from transmembrane precursors that contain one or several EGF structural units in their extracellular domain. Many of these transmembrane precursors are biologically active and seem to play a role in juxtacrine stimulation of adjacent cells. The cDNA for HB-EGF encodes a 204 amino acid residue transmembrane protein that is proteolytically cleaved to generate the soluble HB-EGF. Like EGF, TGF-alpha , and AR; HB-EGF binds to the EGF receptor and activates the receptor tyrosine kinase. HB-EGF is reported to be a more potent SMC mitogen than EGF. It has been suggested that the differential activities found for HB-EGF compared to EGF may be mediated by the heparin-binding properties of HB-EGF. A diphtheria toxin receptor that mediates the endocytosis of the bound toxin has been cloned and found to be identical to the transmembrane HB-EGF precursor.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for HB-EGF Antibody (MAB2591)(3)

Publications using MAB2591

• Bauer, L;Edwards, J;Heil, A;Dewitt, S;Biebermann, H;Aeschlimann, D;Knäuper, V; Mesenchymal Transglutaminase 2 Activates Epithelial ADAM17: Link to G-Protein-Coupled Receptor 56 (ADGRG1) Signalling International journal of molecular sciences 2024-02-16 [PMID: 38397010] (Neutralization, Human)
• S Müller-Deu, L Seefried, M Krug, F Jakob, R Ebert Epidermal growth factor as a mechanosensitizer in human bone marrow stromal cells Stem Cell Res, 2017-08-18;24(0):69-76. 2017-08-18 [PMID: 28843157] (Functional Assay, Human)
• Casas-Gonzalez P, Garcia-Sainz JA Role of epidermal growth factor receptor transactivation in alpha1B-adrenoceptor phosphorylation. Eur. J. Pharmacol., 2006-05-27;542(1):31-6. 2006-05-27 [PMID: 16828079] (Neutralization, Rat)

Bioinformatics

• Gene Symbol: HBEGF
• Uniprot:
  • Q53H93()